Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant tislelizumab plus gemcitabine/cisplatin in muscle-invasive bladder cancer
ChiCTR2100043195Phase 2Completed
- Sponsor
- Chinese PLA General Hospital
- Start
- Mar 2021
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab, gemcitabine and cisplatin in transitional cell carcinoma of the bladder (TCC) and muscle-invasive bladder cancer (MIBC), sponsored by Chinese PLA General Hospital. Primary endpoints: Pathologic complete response and One-year bladder-intact disease-free survival. Started Mar 2021; status: completed.
02
Drugs
tislelizumabgemcitabinecisplatin
03
Conditions
transitional cell carcinoma of the bladder (TCC)muscle-invasive bladder cancer (MIBC)
Beyond the preview
Go deeper on ChiCTR2100043195.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100043195.